Alimera Sciences (ALIM) Shares are Down -8.02%

Alimera Sciences (ALIM) : During the past 4 weeks, traders have been relatively bearish on Alimera Sciences (ALIM), hence the stock is down -0.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.18% relative to the S&P 500. The 4-week change in the price of the stock is -0.67% and the stock has fallen -8.02% in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.36% and the 50-Day Moving Average is 7.61%.The 200 Day SMA reached 19.03%


Alimera Sciences (NASDAQ:ALIM): The stock was completely flat for the day, closing at $1.49 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.50, the stock touched an intraday high of $1.54 and a low of $1.44. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.49. The total trading volume on Friday was 574,762.

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye, or retina. The Companys commercial product is ILUVIEN, which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.